BR112018000112A2 - composições farmacêuticas que compreendem um antagonista de alfa 4 integrina para uso no tratamento de condições inflamatórias oculares - Google Patents

composições farmacêuticas que compreendem um antagonista de alfa 4 integrina para uso no tratamento de condições inflamatórias oculares

Info

Publication number
BR112018000112A2
BR112018000112A2 BR112018000112-0A BR112018000112A BR112018000112A2 BR 112018000112 A2 BR112018000112 A2 BR 112018000112A2 BR 112018000112 A BR112018000112 A BR 112018000112A BR 112018000112 A2 BR112018000112 A2 BR 112018000112A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
alpha
treatment
inflammatory eye
eye conditions
Prior art date
Application number
BR112018000112-0A
Other languages
English (en)
Inventor
Hans-Peter Krauss Achim
Original Assignee
Axerovision, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision, Inc. filed Critical Axerovision, Inc.
Publication of BR112018000112A2 publication Critical patent/BR112018000112A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a invenção se refere a antagonistas da a4 integrina e seu uso em composições farmacêuticas, primariamente composições oftálmicas administradas topicamente. as composições farmacêuticas são úteis para tratar as condições inflamatórias oculares, tais como síndrome do olho seco, uveíte não infecciosa (por exemplo, anterior, intermediária, posterior e panuveíte), conjuntivite não infecciosa, irite ou esclerite em animais e, particularmente, mamíferos, incluindo humanos.
BR112018000112-0A 2015-07-08 2016-07-07 composições farmacêuticas que compreendem um antagonista de alfa 4 integrina para uso no tratamento de condições inflamatórias oculares BR112018000112A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
BR112018000112A2 true BR112018000112A2 (pt) 2018-09-04

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000112-0A BR112018000112A2 (pt) 2015-07-08 2016-07-07 composições farmacêuticas que compreendem um antagonista de alfa 4 integrina para uso no tratamento de condições inflamatórias oculares

Country Status (21)

Country Link
US (3) US10413535B2 (pt)
EP (1) EP3319639B1 (pt)
JP (2) JP6752276B2 (pt)
KR (2) KR20220062688A (pt)
CN (1) CN107921136A (pt)
AU (1) AU2016290197B2 (pt)
BR (1) BR112018000112A2 (pt)
CA (1) CA2989522C (pt)
CL (1) CL2018000057A1 (pt)
ES (1) ES2835274T3 (pt)
HK (1) HK1247120A1 (pt)
IL (2) IL256770B (pt)
MA (2) MA42016A1 (pt)
MX (1) MX2017017163A (pt)
MY (1) MY187552A (pt)
PL (1) PL3319639T3 (pt)
RU (1) RU2018103940A (pt)
TN (1) TN2017000538A1 (pt)
UA (1) UA123728C2 (pt)
WO (1) WO2017006272A1 (pt)
ZA (1) ZA201708601B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004789A (ko) * 2017-03-09 2020-01-14 알리스타 파마슈티컬즈, 인크. 안구 건조증 질환을 위한 펩티드
JP2020523406A (ja) * 2017-05-19 2020-08-06 オクジェン アイエヌシー． 眼科用組成物および使用方法
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114173802A (zh) * 2019-07-26 2022-03-11 急速制药有限责任公司 用于治疗非渗出性黄斑变性和其他眼睛病症的肽
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
CA2628570A1 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
CL2018000057A1 (es) 2018-06-22
RU2018103940A3 (pt) 2019-09-03
MA42016A1 (fr) 2018-03-30
TN2017000538A1 (en) 2019-04-12
AU2016290197A1 (en) 2018-01-04
EP3319639B1 (en) 2020-11-18
JP6752276B2 (ja) 2020-09-09
KR20180041122A (ko) 2018-04-23
UA123728C2 (uk) 2021-05-26
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
KR20220062688A (ko) 2022-05-17
RU2018103940A (ru) 2019-08-08
JP2018521126A (ja) 2018-08-02
ES2835274T3 (es) 2021-06-22
US20200000786A1 (en) 2020-01-02
IL256770A (en) 2018-03-29
IL280827A (en) 2021-04-29
CA2989522C (en) 2022-10-18
ZA201708601B (en) 2019-05-29
US20180200240A1 (en) 2018-07-19
CA2989522A1 (en) 2017-01-12
PL3319639T3 (pl) 2021-03-08
EP3319639A1 (en) 2018-05-16
US20200405703A1 (en) 2020-12-31
MY187552A (en) 2021-09-29
JP2020121985A (ja) 2020-08-13
IL256770B (en) 2021-02-28
CN107921136A (zh) 2018-04-17
HK1247120A1 (zh) 2018-09-21
US10413535B2 (en) 2019-09-17
MX2017017163A (es) 2018-08-09
WO2017006272A1 (en) 2017-01-12
KR102440162B1 (ko) 2022-09-02
AU2016290197B2 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
BR112018000112A2 (pt) composições farmacêuticas que compreendem um antagonista de alfa 4 integrina para uso no tratamento de condições inflamatórias oculares
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
BR112018008877A2 (pt) inibidores de ret
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
AR105299A1 (es) Composición de cuidado de telas que comprende ésteres de poliol instaurados metatesizado
CO2017012991A2 (es) Agonistas de triazol del receptor apj
CY1120729T1 (el) Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112017010173A2 (pt) composição para tratamento de tecido
BR112018009281A8 (pt) composições para tratar atrofia muscular espinhal
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
BR112015032341A2 (pt) conservação de composições para cuidados pessoais
BR112014030685A2 (pt) compostos de n-alquiltriazol como antagonistas de lpar
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112017010177A2 (pt) composição para tratamento de tecido
CY1120295T1 (el) Υποκατεστημενα θειαζολια η οξαζολια ως ανταγωνιστες υποδοχεα ρ2χ7
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]